Bing Xin Song, Erica Vieira, Damien Gallagher, Breno S Diniz, Corinne E Fischer, Alastair J Flint, Nathan Herrmann, Linda Mah, Benoit H Mulsant, Tarek K Rajji, Clement Ma, Krista L Lanctôt
{"title":"有痴呆风险的老年人的血液血管生成标记和认知:有痴呆风险的老年人的血液血管生成和认知标记。","authors":"Bing Xin Song, Erica Vieira, Damien Gallagher, Breno S Diniz, Corinne E Fischer, Alastair J Flint, Nathan Herrmann, Linda Mah, Benoit H Mulsant, Tarek K Rajji, Clement Ma, Krista L Lanctôt","doi":"10.1177/07067437251337627","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectiveChanges in angiogenesis have been shown to contribute to cognitive decline and dementia. We aimed to identify angiogenesis blood markers associated with cognitive performance in older adults with mild cognitive impairment (MCI), remitted major depressive disorder (rMDD), or both (rMDD + MCI) who are at risk for dementia.MethodWe analyzed data from participants with MCI, rMDD, or rMDD + MCI in the Prevention of Alzheimer's Dementia with Cognitive Remediation plus Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Depression study. Elastic net regression was used to select variables associated with cognitive performance among 19 angiogenesis markers and 6 covariates. Linear regressions were used to determine which of the selected angiogenesis markers were associated with cognitive performance, controlling for the selected covariates. Significant angiogenesis markers were independently analyzed without other angiogenesis markers, controlling for covariates, with subgroup analyses in those with and without rMDD.ResultsAngiogenin was the only selected marker associated with cognitive performance (<i>β</i> = 0.28, <i>P</i><sub>adj</sub> = 0.03, <i>f</i>² = .02) when controlling for other selected markers (endothelial cell-specific molecule 1, e-selectin, interleukin-33 [IL-33], oncostatin M, platelet-derived growth factor-AB, IL-33 receptor, and tissue inhibitor of metalloproteinases-1) and selected covariates (age, education, apolipoprotein E ε4 status, diagnosis, and cardiovascular risk factors). When independently analyzed, angiogenin remained positively associated with cognitive performance (<i>β</i> = 0.21, <i>P</i> = 0.01, <i>f</i>² =.02), controlling for the covariates. In subgroup analyses, angiogenin was also associated with cognition in rMDD and rMDD + MCI participants (<i>β</i> =0.50, SE = 0.14, <i>P</i> < 0.001, <i>f</i>² = 0.08) and in MCI-only participants (<i>β</i>= 0.20, SE = 0.09<i>,</i> <i>P</i> = 0.02, <i>f</i>² = 0.02).ConclusionThe association of angiogenin with cognitive performance highlights a potentially novel biological pathway that could influence cognition in older adults at risk for dementia. Angiogenin may protect against cognitive decline, opening new avenues for innovative preventive, or therapeutic interventions.</p>","PeriodicalId":55283,"journal":{"name":"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie","volume":" ","pages":"7067437251337627"},"PeriodicalIF":3.3000,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043659/pdf/","citationCount":"0","resultStr":"{\"title\":\"Blood Angiogenesis Markers and Cognition in Older Adults at Risk for Dementia: Marqueurs sanguins de l'angiogenèse et cognition chez les personnes âgées à risque de démence.\",\"authors\":\"Bing Xin Song, Erica Vieira, Damien Gallagher, Breno S Diniz, Corinne E Fischer, Alastair J Flint, Nathan Herrmann, Linda Mah, Benoit H Mulsant, Tarek K Rajji, Clement Ma, Krista L Lanctôt\",\"doi\":\"10.1177/07067437251337627\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectiveChanges in angiogenesis have been shown to contribute to cognitive decline and dementia. We aimed to identify angiogenesis blood markers associated with cognitive performance in older adults with mild cognitive impairment (MCI), remitted major depressive disorder (rMDD), or both (rMDD + MCI) who are at risk for dementia.MethodWe analyzed data from participants with MCI, rMDD, or rMDD + MCI in the Prevention of Alzheimer's Dementia with Cognitive Remediation plus Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Depression study. Elastic net regression was used to select variables associated with cognitive performance among 19 angiogenesis markers and 6 covariates. Linear regressions were used to determine which of the selected angiogenesis markers were associated with cognitive performance, controlling for the selected covariates. Significant angiogenesis markers were independently analyzed without other angiogenesis markers, controlling for covariates, with subgroup analyses in those with and without rMDD.ResultsAngiogenin was the only selected marker associated with cognitive performance (<i>β</i> = 0.28, <i>P</i><sub>adj</sub> = 0.03, <i>f</i>² = .02) when controlling for other selected markers (endothelial cell-specific molecule 1, e-selectin, interleukin-33 [IL-33], oncostatin M, platelet-derived growth factor-AB, IL-33 receptor, and tissue inhibitor of metalloproteinases-1) and selected covariates (age, education, apolipoprotein E ε4 status, diagnosis, and cardiovascular risk factors). When independently analyzed, angiogenin remained positively associated with cognitive performance (<i>β</i> = 0.21, <i>P</i> = 0.01, <i>f</i>² =.02), controlling for the covariates. In subgroup analyses, angiogenin was also associated with cognition in rMDD and rMDD + MCI participants (<i>β</i> =0.50, SE = 0.14, <i>P</i> < 0.001, <i>f</i>² = 0.08) and in MCI-only participants (<i>β</i>= 0.20, SE = 0.09<i>,</i> <i>P</i> = 0.02, <i>f</i>² = 0.02).ConclusionThe association of angiogenin with cognitive performance highlights a potentially novel biological pathway that could influence cognition in older adults at risk for dementia. Angiogenin may protect against cognitive decline, opening new avenues for innovative preventive, or therapeutic interventions.</p>\",\"PeriodicalId\":55283,\"journal\":{\"name\":\"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie\",\"volume\":\" \",\"pages\":\"7067437251337627\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043659/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/07067437251337627\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Psychiatry-Revue Canadienne De Psychiatrie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/07067437251337627","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
摘要
目的血管生成的改变已被证明会导致认知能力下降和痴呆。我们的目的是确定与轻度认知障碍(MCI)、缓解性重度抑郁症(rMDD)或两者(rMDD + MCI)有痴呆风险的老年人认知表现相关的血管生成血液标志物。方法对轻度认知障碍和抑郁症患者中MCI、rMDD或rMDD + MCI患者的认知修复加经颅直流刺激预防阿尔茨海默氏痴呆的研究数据进行分析。采用弹性网回归从19个血管生成标志物和6个协变量中选择与认知表现相关的变量。线性回归用于确定哪些选定的血管生成标志物与认知表现相关,控制选定的协变量。在没有其他血管生成标志物的情况下,独立分析显著的血管生成标志物,控制协变量,对有和没有rMDD的患者进行亚组分析。结果在控制其他选择的标志物(内皮细胞特异性分子1、E -选择素、白细胞介素-33 [IL-33]、肿瘤抑制素M、血小板衍生生长因子- ab、IL-33受体和金属蛋白酶组织抑制剂-1)和选择的协变量(年龄、教育程度、载脂蛋白E ε4状态、诊断和心血管危险因素)时,血管生成素是唯一与认知能力相关的选择标志物(β = 0.28, Padj = 0.03, f²= 0.02)。当独立分析时,血管生成素与认知表现呈正相关(β = 0.21, P = 0.01, f²= 0.02),控制了协变量。在亚组分析中,血管生成素也与rMDD和rMDD + MCI参与者的认知相关(β= 0.50, SE = 0.14, P f²= 0.08),仅MCI参与者的认知相关(β= 0.20, SE = 0.09, P = 0.02, f²= 0.02)。结论血管生成素与认知表现的关联揭示了一种潜在的新的生物学途径,可能影响痴呆风险老年人的认知。血管生成素可以防止认知能力下降,为创新的预防或治疗干预开辟了新的途径。
Blood Angiogenesis Markers and Cognition in Older Adults at Risk for Dementia: Marqueurs sanguins de l'angiogenèse et cognition chez les personnes âgées à risque de démence.
ObjectiveChanges in angiogenesis have been shown to contribute to cognitive decline and dementia. We aimed to identify angiogenesis blood markers associated with cognitive performance in older adults with mild cognitive impairment (MCI), remitted major depressive disorder (rMDD), or both (rMDD + MCI) who are at risk for dementia.MethodWe analyzed data from participants with MCI, rMDD, or rMDD + MCI in the Prevention of Alzheimer's Dementia with Cognitive Remediation plus Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Depression study. Elastic net regression was used to select variables associated with cognitive performance among 19 angiogenesis markers and 6 covariates. Linear regressions were used to determine which of the selected angiogenesis markers were associated with cognitive performance, controlling for the selected covariates. Significant angiogenesis markers were independently analyzed without other angiogenesis markers, controlling for covariates, with subgroup analyses in those with and without rMDD.ResultsAngiogenin was the only selected marker associated with cognitive performance (β = 0.28, Padj = 0.03, f² = .02) when controlling for other selected markers (endothelial cell-specific molecule 1, e-selectin, interleukin-33 [IL-33], oncostatin M, platelet-derived growth factor-AB, IL-33 receptor, and tissue inhibitor of metalloproteinases-1) and selected covariates (age, education, apolipoprotein E ε4 status, diagnosis, and cardiovascular risk factors). When independently analyzed, angiogenin remained positively associated with cognitive performance (β = 0.21, P = 0.01, f² =.02), controlling for the covariates. In subgroup analyses, angiogenin was also associated with cognition in rMDD and rMDD + MCI participants (β =0.50, SE = 0.14, P < 0.001, f² = 0.08) and in MCI-only participants (β= 0.20, SE = 0.09,P = 0.02, f² = 0.02).ConclusionThe association of angiogenin with cognitive performance highlights a potentially novel biological pathway that could influence cognition in older adults at risk for dementia. Angiogenin may protect against cognitive decline, opening new avenues for innovative preventive, or therapeutic interventions.
期刊介绍:
Established in 1956, The Canadian Journal of Psychiatry (The CJP) has been keeping psychiatrists up-to-date on the latest research for nearly 60 years. The CJP provides a forum for psychiatry and mental health professionals to share their findings with researchers and clinicians. The CJP includes peer-reviewed scientific articles analyzing ongoing developments in Canadian and international psychiatry.